India Pharma Outlook Team | Friday, 01 August 2025
Zydus Lifesciences Limited (Zydus) signed contracts with PAI and two Amplitude Surgical minority shareholders to purchase blocks of shares, which together account for 85.6% of Amplitude Surgical's voting rights and share capital, for €6.25 per share and a total consideration of €256 million (block acquisition).
Due to the fulfillment of all prerequisites and the subsequent completion of the Block Acquisition on July 29, 2025, Zydus currently owns 85.6% of Amplitude Surgical's share capital and voting rights.
Olivier Jallabert, who has invested in the business that has successfully completed the block acquisition, will continue to serve as CEO of Amplitude Surgical. With effect from July 28, 2025, Amplitude Surgical has terminated its June 19, 2018, liquidity contract with Oddo BHF and Natixis in connection with the Block Acquisition.
Also Read: P&G to Set Up Rs 2,000 Cr Psyllium Husk Drug Plant in Gujarat
On July 30, 2025, Zydus will submit a simplified required tender offer for all of Amplitude Surgical's outstanding shares at a price of €6.25 per share, which is comparable to the amount paid for the Block Acquisition. After the offer is completed, Zydus will be able to acquire over 90% of Amplitude Surgical's capital and voting rights thanks to specific tender commitments from seven shareholders, who together account for 4.7% of the company's share capital and voting rights. Zydus will then ask for the implementation of a squeeze-out.
